Abstract
This practical research arises from a growing interest in offering models that provide a measure of the efficiency of pharmaceutical management in the Public Health System, beyond spending per inhabitant or other similar indices that do not incorporate the effects of the environment. The main objective of the paper is to design a tool that can measure the relative efficiency of health systems, with respect to the rational use of medicament based on its regional socioeconomic context. The first step was to check if it is possible to apply the efficiency and productivity analysis models, widely used in the economy and companies. We have carefully chosen the context factors that are pertinent and influential in the final index: demographic, sanitary, economic, and social. After selecting and ordering the context variables of the different regions of Spain, they are normalized using the index number transformation or ‘distance’ to a reference. The weighted sum method is used to build the synthetic indicators. The main contribution of this paper is to propose a relative efficiency indicator that assumes the context of performance and allows a comparison between health organizations. The methodology offered in this manuscript could assist policymakers to make better decisions in order to enhance the productivity of the public pharmaceutical system, and it makes available feedback about past decisions.
Highlights
At a time when the epidemiological crisis of the coronavirus is putting the health systems of all the countries of the world at the razor edge, analyzing the efficiency of the pharmaceutical public systems becomes a fundamental aspect for health managers and politicians
The main objective of the paper is to design a tool that is capable of measuring the relative efficiency of health systems, with respect to the rational use of medicament based on its regional socioeconomic context
Itself to be an appropriate way to measure the relative efficiency of public health management in comparison to other comparable health systems
Summary
At a time when the epidemiological crisis of the coronavirus is putting the health systems of all the countries of the world at the razor edge, analyzing the efficiency of the pharmaceutical public systems becomes a fundamental aspect for health managers and politicians. The utilization of medications carries on rising in the Organization for Economic Co-operation and Development (OECD) countries and forcing up pharmaceutical spending. Cost-containment plans and patent expirations of some top-selling products have put a downwards pressure on pharmaceutical payments. The spread of high-cost specialty drugs will be the primary handler of health spending progression in the years (Belloni et al 2016). About concrete characteristics of the pharmaceutical industry, such as research and development intensity, patents, the uncertainty of the product development process, lack of performance Evaluating the efficiency of health care systems concerning the frontier specified by a comparable sample of countries or regions could be helpful in identifying whether there is a potential correction in the use of resources (Varabyova and Müller 2016).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
